Shanghai Jeyou Pharmaceutical Technology Co., Ltd. was founded in 2018 in Pudong, Shanghai, and specializes in the research, development, manufacturing, and commercialization of innovative drugs. Leveraging its exceptional drug development capabilities and integrated R&D, manufacturing, and sales model, Jeyou Pharmaceutical is committed to rapidly bringing its proprietary innovative drugs to the global market to address unmet medical needs.

Guided by clinical value, Jeyou Pharma focuses on a “3+1” indication matrix encompassing oncology, nephrology, pain, and autoimmune diseases. The company has established specialized departments covering the entire drug development lifecycle and has built a comprehensive R&D system spanning basic research, preclinical studies, clinical trials, pharmacovigilance, and new drug registration and commercialization. Jeyou Pharma possesses multiple advanced technology platforms in the fields of large biomolecules and small chemical molecules. Led by scientists with extensive drug development experience, the R&D team identifies drug targets with unique clinical value and has mastered core R&D technologies and processes with proprietary intellectual property rights. Currently, there are over 40 projects in development, 19 of which have entered the clinical phase domestically and internationally.

Jeyou Pharma regards quality as the lifeblood of the company. To meet the market demand for high-quality innovative drugs, the company has established two state-of-the-art drug manufacturing bases in Hangzhou, Zhejiang, and Wuxi, Jiangsu. Integrating world-class pharmaceutical technologies and equipment, and guided by concepts such as QbD (Quality by Design) and and PDCA (Plan-Do-Check-Act), the company has established an internationally advanced quality management system compliant with ICH Q10. It implements full lifecycle control over all product manufacturing and supply chains, earning market and customer trust through product quality.

In mainland China, Jeyou Pharma has developed strong commercialization capabilities and is actively integrating into the global market, having successfully exported intellectual property rights for multiple innovative drugs. While contributing Chinese wisdom to human health, Jeyou Pharmaceuticals actively introduces internationally leading pharmaceuticals into the Chinese market to meet the country’s growing clinical needs.

Looking ahead, Jeyou Pharmaceuticals will continue to advance the development of innovative drugs, continuously build new productive forces, and strive to become an internationally advanced, modern, and innovative pharmaceutical enterprise, working tirelessly to improve human health!

2018

2018

Company Founding

Company Founding

40+

40+

Projects in Progress

Projects in Progress

19

19

Clinical Projects

Clinical Projects

Mission

Serving the World and Benefiting the People; Trusted by All

Vision

To become a modern, innovative pharmaceutical company that is internationally advanced and a leader in China

Values

Pragmatism, Transformation, Integration, and Striving

History

· May: Named one of the “Top 100 Enterprises” on the Shanghai Specialized, Refined, Unique, and Innovative Enterprise Brand Value List

· September: Shortlisted for the “2024 Shanghai Top 100 Innovative High-Tech Enterprises List”

· December: Granted overseas rights to RAPT for the long-acting IgE antibody JYB1904

· December: Nine innovative drug projects in Phase II clinical trials

· August: Recognized as a “Specialized, Refined, Unique, and Innovative” SME in Shanghai and designated as a Shanghai Enterprise Technology Center

· December: JMKX1899 included in the list of breakthrough therapy candidates

· December: Advanced 22 innovative drug projects into clinical trials

· May: Licensed overseas rights to ORION for the non-opioid analgesic JMKX000623

· August: Licensed global rights to Genentech (a Roche subsidiary) for the oral AR degrader JMKX002992

· September: Inauguration of the Shanghai Kangqiao headquarters

· September: Construction begins on the small-molecule manufacturing facility in Hangzhou

· December: 1 program completed Phase I clinical trials; 6 programs entered clinical trials; 7 INDs approved

· October: Construction begins on the Wuxi Macromolecule Research Base

· November: Overseas rights to the KRAS inhibitor JMKX1899 licensed to Huya Bio International

· November: Designated as a National High-Tech Enterprise

· March: The Biomacromolecules Laboratory was completed and put into operation

· May: Shanghai Jiyu Pharmaceutical Technology Co., Ltd. was incorporated

Business Philosophy

Business Philosophy

Dedication, Expertise, Innovation, Entrepreneurship

Focus

Focusing on R&D to Build a Competitive Edge

Professional

Leverage the team’s proven track record of success

Innovation

Innovation in Business Models and Management

Entrepreneurship

An entrepreneurial spirit characterized by frugality, efficiency, and hard work

Company Honors

Shanghai Municipal Enterprise Technology Center

High-Tech Enterprise Certificate

2024 Shanghai “Specialized, Refined, Unique, and Innovative” Enterprises Brand Value Ranking: “Top 100 Companies”

Green Development

Jeyou Pharma has integrated ESG (Environmental, Social, and Governance) into a core component of its business strategy. We fully recognize that ESG is not only a manifestation of corporate social responsibility but also a key driver of sustainable corporate growth. Therefore, Jeyou Pharmaceuticals benchmarks against advanced international ESG standards and best practices. Focusing on five key dimensions—compliance and fairness, healthcare, social welfare, employee development, and green development—we are comprehensively and steadfastly advancing our ESG initiatives. We are continuously optimizing environmental management, enhancing social responsibility awareness, and strengthening corporate governance, striving tirelessly to achieve our goals of green, harmonious, and mutually beneficial development.